Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of pneumonia prevalence and antimicrobial resistance in GhanaGhana's pneumonia rate hits 22 percent with one region most at risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note high pneumonia prevalence and >70% resistance to key antibiotics in Ghana.

This systematic review and meta-analysis evaluates the epidemiology of pneumonia and associated antimicrobial resistance within Ghana. The study encompasses a large sample of 124 582 participants, including children younger than 5 years, elderly individuals, hospitalized patients, and community children. The primary outcome assessed was the pooled prevalence of pneumonia across these diverse groups.

The analysis reveals a pooled pneumonia prevalence of 22.01%. Regional variations were substantial, with rates reaching 32.31% in Greater Accra and Northern regions, while Upper West reported 4.83%. Specific subgroups showed distinct patterns, such as 17.79% prevalence in children under 5 years and 21.49% in community children. Hospitalized patients exhibited a prevalence of 22.14%.

Mortality rates for pneumonia were determined to be 3.07%. Antimicrobial resistance was notably high, with rates greater than 70% observed for co-trimoxazole, gentamicin, and tetracycline. The authors note that comprehensive data on prevalence and distribution remain limited. No safety data, adverse events, or tolerability were reported in the source material.

The authors conclude that these findings provide critical evidence for targeted public health strategies. Given the high resistance rates and regional disparities, clinicians and public health officials should consider these data when formulating treatment guidelines and resource allocation plans for pneumonia management in the region.

Pneumonia is a serious lung infection that can make it hard to breathe. In Ghana, it is a leading cause of sickness and death, especially for young children and older adults. A new review pulls together data from 21 studies to show how common pneumonia is and where the risks are highest.

This matters now because families and doctors need clear facts to plan care and prevention. The review looked at more than 124,000 people across Ghana. It measured how many have pneumonia, which regions are most affected, and how well current treatments work.

But here is the twist. The overall rate is striking, yet the gap between regions is even more important. Some areas have much higher rates than others. That means local conditions and environment play a big role in who gets sick.

Think of pneumonia like a lock and key. The bacteria or virus is the key, and the body’s defenses are the lock. When the key fits, infection takes hold. Things like indoor air pollution and seasonal changes can make the lock weaker, so the key slips in more easily.

The review used a method called meta-analysis, which combines results from many studies to give a clearer picture. Researchers searched major medical databases and included studies that measured pneumonia in Ghana. They checked study quality and used standard tools to reduce bias.

They found that about 22 out of every 100 people in Ghana have pneumonia. That is the pooled prevalence. The rate was highest in studies from the Greater Accra and Northern regions, at about 32 percent. The lowest rate was in the Upper West region, at about 5 percent.

For children under 5, the rate was about 18 percent. Hospitalized patients had a slightly higher rate than children in the community. The overall death rate from pneumonia was about 3 percent.

This does not mean every person in Ghana has pneumonia.

The review also looked at which germs cause pneumonia and how they respond to antibiotics. The most common germ was Streptococcus pneumoniae. This bacterium showed high resistance to several common antibiotics, including co-trimoxazole, gentamicin, and tetracycline. Resistance rates were above 70 percent for some drugs.

That means many standard treatments may not work well. Doctors may need to choose different antibiotics based on local resistance patterns. It also underscores the need for better prescribing practices and stronger infection control.

Indoor air pollution and seasonal changes were key risk factors. Burning wood or charcoal indoors can irritate the lungs and make infections more likely. Rainy seasons can also increase exposure to germs. These factors help explain why some communities face higher rates.

The Greater Accra and Northern regions showed the highest prevalence. This could be due to population density, access to care, or environmental factors. The Upper West region had the lowest rate, but the review notes that data from some areas are still limited.

The review included studies from hospitals and communities. It used random-effects models to account for differences between studies. Sensitivity analysis helped check whether the results were stable. Study quality was assessed with standardized checklists.

What does this mean for patients and caregivers? If you live in Ghana, be aware of pneumonia symptoms, such as cough, fever, and trouble breathing. Seek care early, especially for young children and older adults. Talk to your doctor about which antibiotics are likely to work in your area.

Limitations of the review include the mix of studies from different regions and settings. Some areas had fewer studies, so the picture may change as more data come in. The review also focused on published studies, which may miss local reports.

What happens next? The authors call for more research on environmental drivers, better surveillance of antibiotic resistance, and stronger focus on underreported regions. Public health teams can use these findings to target prevention and improve treatment guidelines.

Pneumonia remains a major challenge in Ghana, but clear data can guide action. With better awareness, cleaner air, and smarter antibiotic use, the burden can be reduced.

Study Details

Study typeMeta analysis
Sample sizen = 582
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Pneumonia is a major cause of morbidity and mortality in Ghana, especially among children <5 y of age and the elderly. However, comprehensive data on its prevalence and distribution remain limited. This systematic review addresses this gap by analysing the prevalence, regional variations, risk factors, antimicrobial resistance and mortality rates of pneumonia in Ghana. We searched PubMed, ScienceDirect, Web of Science and African Journals Online databases, including 21 studies with a total of 124 582 participants. A random-effects meta-analysis estimated pooled prevalence and subgroup differences based on age, region and participant type. Heterogeneity was assessed using the I2 test and meta-regression, with sensitivity analysis also conducted. Study quality was evaluated using standardized Joana Briggs Institute checklists for prevalence studies. The pooled prevalence of pneumonia in Ghana was 22.01%, with significant regional variations. The highest prevalence was observed in a study conducted in the Greater Accra and Northern regions (32.31%), while the lowest was in the Upper West (4.83%). The prevalence in children <5 y of age was 17.79%. Hospitalized patients had a higher prevalence (22.14%) than community children (21.49%). Streptococcus pneumoniae was the most common pathogen, with high resistance (>70%) to co-trimoxazole, gentamicin and tetracycline. Key risk factors included indoor air pollution and seasonal changes. The mortality rate for pneumonia was found to be 3.07%. This systematic review highlighted significant regional disparities, pathogen resistance patterns and environmental risk factors that shape the burden of pneumonia in Ghana, providing critical evidence for targeted public health strategies. The findings highlight avenues for future research, including environmental drivers of transmission, focusing on underreported regions and surveillance of antibiotic resistance of pathogens isolated from pneumonia patients.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.